The use of a gp96 peptide complex as an individual multivalent tumor vaccine has been shown to be a safe, effective, and promising adjuvant immunotherapy in clinical trials; however, larger and higher quality clinical trials are still needed. The gene discussed is HSP90B1; the disease is neoplasm.